Aclidinium bromide/formoterol Fixed-Dose Combination
D6570C00002
Phase 3 small_molecule completed
Quick answer
Aclidinium bromide/formoterol Fixed-Dose Combination for COPD is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- COPD
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed